<DOC>
	<DOCNO>NCT00787891</DOCNO>
	<brief_summary>The purpose study access effectiveness safety oral rabeprazole treatment acid-related disorder pediatric patient , focus specifically manifestation GERD ( symptomatic erosive type ) .</brief_summary>
	<brief_title>A Study Safety Effectiveness Rabeprazole Treatment Gastroesophageal Reflux Disease ( GERD ) Pediatric Patients</brief_title>
	<detailed_description>This randomize , double-blind study consist two part . In Part 1 , study consist 3 phase : 14-day screening phase , double-blind treatment phase 12 week compare two dos study drug ( 0.5 mg/kg 1.0 mg/kg group base patient 's body weight ) , end-of-study early withdrawal phase follow Part 2 , consist double-blind treatment continuation patient achieve heal short-term double-blind treatment phase . The double-blind maintenance treatment phase last 24 week conclude end-of-study/early withdrawal visit . During Part 1 , patient screen diagnosis erosive non-erosive Gastroesophageal Reflux Disease ( GERD ) make base clinical symptom confirm endoscopy/histology biopsy . Patients enrol study receive study drug daily 12 week . Each day , parent/caregiver record presence severity pre-specified GERD symptom . At Weeks 4 8 , investigator evaluate response treatment assessment GERD symptom . At Week 12 , investigator perform endoscopy esophagus biopsy confirm histological healing occur . If patient continue , additional study drug dispense ( dose take short-term double-blind treatment phase ) patient schedule return every 8 week study drug discontinue Week 24 ( Part 2 ) double-blind maintenance treatment phase . At final visit maintenance treatment phase Week 24 ( Part 2 ) , assessment include endoscopy esophagus biopsy perform patient . Assessments effectiveness include endoscopic histological grading biopsy sample , GERD symptom severity score ( symptoms severity rat daily parent/caregiver electronic diary ) , overall GERD symptom relief , Clinical Global Impression Improvement ( CGI-I ) score , Global Treatment Satisfaction Score . Safety assessment include monitor concomitant therapy adverse event throughout study , clinical laboratory testing ( include hematology , clinical chemistry , urinalysis ) , vital sign , physical examination include height , weight , Tanner stag . Oral rabeprazole 2.5 capsule 5 mg capsule , give daily dose 0.5 mg/kg 1.0 mg/kg ; short-term treatment phase 12 week ; long-term maintenance treatment phase 24 week .</detailed_description>
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Rabeprazole</mesh_term>
	<criteria>History least 1 Gastroesophageal Reflux Disease ( GERD ) symptom within 3 month screen Positive esophagogastroduodenoscopy Signed informed consent Female patient ( menstruate ) must practice birth control Patients history esophagitis Patients milk protein allergy Patients take Proton Pump Inhibitors H2blockers within 3 day Patients take sucralate medication affect gastrointestinal motility Patients H. pylori Patients lab value outside normal age appropriate range Patients participate another trial within 30 day screen Patients allergy Proton Pump Inhibitors</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Gastroesophageal Reflux Disease ( GERD )</keyword>
	<keyword>Erosive Gastroesophageal Reflux Disease</keyword>
	<keyword>Ulcerative Gastroesophageal Reflux Disease</keyword>
	<keyword>Endoscopy</keyword>
	<keyword>Pediatrics</keyword>
	<keyword>Rabeprazole</keyword>
</DOC>